|
|
|
LifeScienceHistory.com - Check us out on Instagram
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Cellerant Therapeutics, Inc.
| | | Phone: | (650) 232-2122 | Fax: | (650) 232-5495 | Year Established: | 2001 | Main Contact: | Ram Mandalam, President & CEO | | Other Contacts: | Joseph Seroogy, VP, Project Management & QA Gautam Banik, VP, Manufacturing & Process Science William Reed, VP, Clinical Development Jagath Reddy Junutula, VP, Antibody Discovery & Development Rodney Young, CFO Timothy Fong, VP, Cellular Technologies
| | Company Description | Cellerant is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerants lead product, CLT-008 is currently in two Phase 1/2 clinical trials evaluating safety in patients undergoing treatment for AML and cord blood transplantation. The Company is developing CLT-008 as a first-in-class, off-the-shelf, cellular therapeutic for treatment of chemotherapy induced neutropenia, protection from exposure to acute radiation and facilitating cord blood transplantation. The Company also has a cancer stem cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome. The Companys lead antibody program is a potential first-in-class, antibody development candidate targeting AML cancer stem cells displaying potent preclinical efficacy. | |
|
|
|
|
|